Home > Cardiology > ACC 2022 > Highlighted Original Research > New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?

New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?

Presented By
Dr Mark Svet, University of Colorado, USA
Conference
10:07:09pm> hello nurse from conference
Trial
VOYAGER-PAD
New findings from VOYAGER PAD indicate that patients with chronic kidney disease (CKD) and concomitant peripheral artery disease (PAD) showed a consistent 4.7% absolute risk reduction of hospitalisation after lower-extremity revascularisation when taking low-dose rivaroxaban plus aspirin compared with aspirin alone. Moreover, the risk of bleeding was not increased. Internal medicine resident Dr Mark Svet (University of Colorado, CO, USA) presented the subgroup analysis of VOYAGER PAD (NCT02504216) participants with and without CKD [1,2]. VOYAGER PAD randomised 6,564 individuals to receive either the rivaroxaban vascular dose at 2.5 mg twice daily plus aspirin 100 mg once daily (n=3,286) or aspirin alone at 100 mg once daily (n=3,278), with a median follow-up of 28 months [3]. The primary efficacy and safety endpoints were met, which illustrated the supe...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on